Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Helix BioPharma ( (TSE:HBP) ).
Helix BioPharma unveiled new data on its CEACAM6-directed antibody-drug conjugate program at the 16th Annual World ADC London conference, highlighting a proprietary VHH-based nanobody with tumor-selective binding. The company said the data support development of next-generation ADCs designed to deliver potent payloads directly to cancer cells while sparing healthy tissue, reinforcing Helix’s positioning as an emerging player in CEACAM6-targeted oncology and potentially broadening treatment options for multiple hard-to-treat epithelial cancers.
Company scientists emphasized that CEACAM6 is highly expressed across a range of epithelial tumors and linked to poor outcomes, while being largely absent in healthy tissue. The presentation, which drew strong interest from industry peers at the high-profile ADC forum, builds on clinical signals from L-DOS47 in non-small cell lung cancer and may help attract further scientific collaboration and stakeholder attention to Helix’s growing ADC platform.
The most recent analyst rating on (TSE:HBP) stock is a Hold with a C$2.00 price target. To see the full list of analyst forecasts on Helix BioPharma stock, see the TSE:HBP Stock Forecast page.
Spark’s Take on TSE:HBP Stock
According to Spark, TipRanks’ AI Analyst, TSE:HBP is a Neutral.
The score is held down primarily by weak fundamentals—no revenue, ongoing losses, and continued cash burn—partly offset by a stronger balance-sheet position (low leverage) and improving loss/cash-flow trends. Technicals are supportive with the stock above key moving averages, while valuation is difficult to support due to losses and no dividend yield.
To see Spark’s full report on TSE:HBP stock, click here.
More about Helix BioPharma
Helix BioPharma is a clinical-stage oncology company focused on developing targeted therapies for hard-to-treat cancers. Its lead program, Tumor Defense Breaker L-DOS47, is an antibody-enzyme conjugate targeting CEACAM6-expressing tumors in non-small cell lung cancer, complemented by next-generation bispecific ADCs in discovery and two oral pre-IND candidates for leukemia relapse and advanced cancers.
Average Trading Volume: 2,037
Technical Sentiment Signal: Buy
Current Market Cap: C$152.8M
See more insights into HBP stock on TipRanks’ Stock Analysis page.